Literature DB >> 30347274

Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.

Sang-Min Hyun1, Benjamin Joon Lee2, Sharif Md Abuzar1, Soohun Lee1, Yechan Joo1, Seung-Hyeon Hong1, Han Kang2, Kyung-Ae Kwon3, Sitaram Velaga4, Sung-Joo Hwang5.   

Abstract

Celecoxib (CEL) is a selective cyclooxygenase-2 (COX-2) inhibitor therapeutically indicated for the treatment of rheumatoid arthritis, osteoarthritis, acute pain, and inflammation. However, its poor solubility and dissolution rate significantly hinders its broader application. In this study, eutectic mixtures, as binary pharmaceutical compositions of CEL with adipic acid (ADI) and saccharin (SAC), were identified through a phase diagram and Tammann's triangle intended to improve the wettability and dissolution rate of poorly water-soluble CEL. The contact angles at 0s in the liquid-solid interface were approximately θs (theta) 79.7 ± 0.50° and 86.65 ± 0.45° for CEL-ADI and CEL-SAC, respectively, which were much lower than the value obtained for CEL (92.05 ± 0.75° θ). Moreover, a comparison of the disk intrinsic dissolution rate and powder dissolution properties demonstrated that eutectic mixtures significantly increased the dissolution rate compared with CEL and physical mixtures. A general relationship was elucidated and indicated that the dissolution rate was increased as the contact angle decreased (correlation coefficient, r = 0.9966 ± 0.0031). Therefore, CEL-ADI and CEL-SAC eutectics may offer a novel formulation strategy to enhance the solubility and oral bioavailability of CEL.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Adipic acid (PubChem CID: 196); Celecoxib; Celecoxib (PubChem CID: 2662); Citric acid (PubChem CID: 311); Contact angle; Eutectic; Evaporation crystallization; Fumaric acid (PubChem CID: 444972); Malic acid (PubChem CID: 525); Nicotinamide (PubChem CID: 936); Phase diagram; Saccharin (PubChem CID: 5143); Succinic acid (PubChem CID: 1110); Tammann’s Triangle; Urea (PubChem CID: 62705)

Mesh:

Substances:

Year:  2018        PMID: 30347274     DOI: 10.1016/j.ijpharm.2018.10.044

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Drug Solubility Enhancement through the Preparation of Multicomponent Organic Materials: Eutectics of Lovastatin with Carboxylic Acids.

Authors:  Andrea Mariela Araya-Sibaja; José Roberto Vega-Baudrit; Teodolito Guillén-Girón; Mirtha Navarro-Hoyos; Silvia Lucia Cuffini
Journal:  Pharmaceutics       Date:  2019-03-09       Impact factor: 6.321

2.  Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures.

Authors:  Eric Ofosu Kissi; Keyoomars Khorami; Thomas Rades
Journal:  Pharmaceutics       Date:  2019-11-24       Impact factor: 6.321

3.  Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process.

Authors:  Mac Arturo Murillo-Fernández; Ernesto Montero-Zeledón; Ariadna Abdala-Saiz; José Roberto Vega-Baudrit; Andrea Mariela Araya-Sibaja
Journal:  Pharmaceutics       Date:  2022-02-16       Impact factor: 6.321

4.  Synthesis of Celecoxib-Eutectic Mixture Particles via Supercritical CO2 Process and Celecoxib Immediate Release Tablet Formulation by Quality by Design Approach.

Authors:  Seung-Hyeon Hong; Linh Dinh; Sharif Md Abuzar; Eun Seok Lee; Sung-Joo Hwang
Journal:  Pharmaceutics       Date:  2022-07-26       Impact factor: 6.525

Review 5.  Improving the Physicochemical and Biopharmaceutical Properties of Active Pharmaceutical Ingredients Derived from Traditional Chinese Medicine through Cocrystal Engineering.

Authors:  Danyingzi Guan; Bianfei Xuan; Chengguang Wang; Ruitao Long; Yaqin Jiang; Lina Mao; Jinbing Kang; Ziwen Wang; Shing Fung Chow; Qun Zhou
Journal:  Pharmaceutics       Date:  2021-12-15       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.